IDEXX LABORATORIES INC /DE (IDXX): what the price assumes

In the published model solve dated 2026-Q2, anchored at $554.99, IDEXX LABORATORIES INC /DE (IDXX) is priced for +35.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-03.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/IDXX

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 10.6% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: elevated (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=15)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• IDEXX runs a razor-and-blade model in veterinary diagnostics: it places analyzers in animal clinics, then earns high-margin recurring revenue from the consumables, test kits, and reference-lab services those instruments pull through, a stream the company calls its recurring diagnostic revenue.
• The quality is exceptional: a roughly 32% operating margin, a return on equity above 70%, and a balance sheet with almost no net debt, which is why the stock commands a premium few healthcare names earn.
• The defining risk is demand sensitivity: recurring revenue ultimately depends on pets being brought to the vet, and a weak economy that trims discretionary pet spending would slow the visit volumes the company tracks closely.

Bull Case

IDEXX is a mature compounder, and reading it through that lens is what makes the premium intelligible. This is not a turnaround or a speculative bet; it is a dominant franchise that has been growing recurring revenue at double digits for years and just did it again. First-quarter 2026 revenue rose 14% as reported and 11% organically to $1,141 million, led by Companion Animal Group growth of 15%, and earnings per share rose 17% to $3.47. For a company this size to grow organic revenue at 11% is unusual, and it reflects a structural position rather than a cyclical bounce. On the strength of the quarter, management raised full-year 2026 guidance to $4.67 to $4.76 billion in revenue.

The moat is the installed base and the recurring revenue it generates. IDEXX places diagnostic analyzers in veterinary clinics, and while the instruments themselves are sold once, the company is explicit that the real economics come from the recurring stream: revenues from its VetLab consumables, SNAP rapid-assay test kits, reference-laboratory services, and maintenance agreements. Once a clinic standardizes on IDEXX instruments and workflow, it keeps buying the consumables that run on them, and the company's long-term growth depends on growing volumes at existing customers and adding new ones, both of which it is doing. CAG Diagnostics recurring revenue grew about 11% organically in the quarter, with growth in both the U.S. and internationally. That is high-margin, sticky, annuity-like revenue.

The financial profile is close to ideal, which is why only the growth lens reaches the price. Return on equity is above 70%, return on invested capital near 15% sits well above the cost of capital, and the operating margin runs about 32%. Net debt is tiny at roughly $249 million, a fraction of a single year's operating income, with interest coverage above 36 times, and the share count is falling at about 1.6% a year. The business converts its earnings to cash and returns it. The bull case for IDEXX is the bull case for any great compounder: a durable, recurring revenue base in a structurally growing market, run by a management team that keeps widening the lead, and worth paying up for because the static methods cannot price decades of compounding.

Bear Case

The external variable with the most leverage on IDEXX is one the company does not control: how often pets get to the vet. The recurring revenue that powers the model is downstream of clinic visits, and clinic visits are downstream of discretionary household spending on animals. IDEXX is candid about this in its own filing, warning that "A weak worldwide economy, or actual or perceived economic weakness in any significant geography, could result in reduced demand for our products and services", and it monitors patient-visit and clinic-revenue data precisely because that trend is the leading indicator of its own growth. Veterinary visit volumes have been a soft spot industry-wide in recent years, and the company's double-digit recurring growth has come more from price and test-menu expansion than from rising visits. If a recession or a sustained pullback in pet spending pushes visit volumes down, the volume half of the growth algorithm weakens, and the price assumes that does not happen.

The valuation has fully priced the franchise quality, which leaves no margin for disappointment. At $561.65 (as of June 27, 2026), no family of valuation method reaches the price. The asset and earnings-power lenses, which read book value and capitalize current profit, land near $77 to $245 per share. Peer multiples land near $222 to $408. Even the forward-growth models mostly fall short, with only the exit-multiple DCF reaching the price by holding today's elevated EBITDA multiple flat. The inversion makes the bet stark: to justify the price, IDEXX has to sustain very high growth for years, and the implied growth assumption is among the most demanding the model produces. When a stock is priced for sustained best-in-class growth, even a modest deceleration, organic growth slowing from 11% toward high single digits, can trigger a sharp multiple compression, because the premium was the growth.

Competition and pricing scrutiny are the slower-burning risks. IDEXX competes with Zoetis and other diagnostics and animal-health players, and its premium pricing depends on continued product differentiation; the company itself notes that its success depends on differentiating its products in a way that justifies a premium price. Any erosion of that differentiation, a competitor closing the gap on instrument capability or reference-lab turnaround, would pressure both volume and price. The downside is not financial fragility; the balance sheet is pristine and there is no solvency question. It is valuation risk in its purest form: a wonderful business priced for perpetual excellence, where the path to loss is not the company failing but the company merely growing a little slower than the price requires.

Valuation

The price is a bet on sustained, best-in-class growth from an already premium-priced compounder. The inversion reads the embedded growth as very high, among the most demanding assumptions in the model, sustained for years on top of a roughly 32% operating margin. For IDEXX, the relevant assumption is not margin expansion, the margins are already excellent, but the durability of double-digit recurring-revenue growth. That is a bet on the installed base continuing to compound and the veterinary diagnostics market continuing to expand.

How far the price sits from the methods is wide and nearly unanimous. The asset and earnings-power lenses, anchored on a thin book value of $19.41 per share against an extraordinary return on equity above 70%, land between roughly $77 and $245, because even a very high return on a small book generates a value below the price when no growth is credited. Peer multiples land near $222 to $408. The forward-growth models reach highest, but only the exit-multiple DCF, which holds today's roughly 31-times EBITDA multiple flat, reaches the price. The pattern is clear: the price is a bet beyond what any standard frame supports on current numbers, defensible only by crediting durable compounding the static methods structurally cannot price. The spread between the price and the static lenses is large, three to five times on the earnings-power methods, and that spread is the quality premium.

Solvency is a non-issue and reinforces the quality story. Net debt of about $249 million is a rounding error against $1.4 billion of trailing operating income, interest coverage runs above 36 times, and the share count is falling at about 1.6% a year as the company returns cash. There is no downside risk from the balance sheet whatsoever. The decisive number for IDEXX is not a valuation output; it is the durability of the recurring-revenue growth rate, because the entire premium rests on that growth persisting, and the variable most likely to interrupt it, veterinary visit volumes tied to discretionary pet spending, sits outside the company's control.

Catalysts

IDEXX reported first-quarter 2026 results on May 5, 2026, and raised its outlook. Revenue rose 14% as reported and 11% organically to $1,141 million, driven by Companion Animal Group growth of 15% as reported and 12% organic, and earnings per share increased 17% to $3.47. CAG Diagnostics recurring revenue grew about 11% organically, with roughly 11% growth in the U.S. and 12% internationally, reflecting net customer gains, volume gains, and expansion of the premium instrument installed base.

On the strength of the quarter, management lifted full-year 2026 guidance to revenue of $4.67 to $4.76 billion and adjusted earnings per share of $14.45 to $14.90. The forward watch items are the drivers of the recurring stream: the trajectory of veterinary clinic visit volumes, which the company tracks as a leading indicator and which has been a soft spot for the industry, and the continued expansion of the premium instrument installed base that pulls consumables through. Because the stock is priced for durable double-digit growth, the central question each quarter is whether organic recurring-revenue growth holds at its recent pace or begins to decelerate, since that growth is what the valuation depends on.

Peer Cohorts (Per Segment, With Filing Citations)

CAG (Companion Animal Group) (reported)

• ZTS (Zoetis Inc.)
• FY2025 10-K: …to a lower benefit in the U.S. related to foreign-derived intangible income, partially offset by a more favorable jurisdictional mix of earnings (which includes the impact of the location of pre-tax earnings, tax impact of permanent differences and repatriation activity) and higher net discrete tax benefits. 42 |…
• FY2025 10-K: …products with the same primary active pharmaceutical or biological ingredient(s) as a single product line, even if such products include different brands, dosages, formulations or indicated species. For vaccines, we typically consider a group of vaccines as a single product line if they share the same brand. We have…
• ELAN (Elanco Animal Health Incorporated)
• FY2025 10-K: …Cats, Dogs Zenrelia™ JAK inhibitor in the form of a once-daily oral tablet targeting control of pruritus and atopic dermatitis in dogs. Dogs Farm Animal Products Product Description Primary Species AviPro™ (vaccines) Includes multiple products that collectively protect against Newcastle disease, infectious…
• FY2025 10-K: …offers a convenient at home solution for osteoarthritis. Farm Animal: Our farm animal products help producers improve animal health and wellbeing and raise livestock more sustainably, delivering more food while using fewer resources and enhancing the integrity of the food supply. Our farm animal portfolio of products…
• NEOG (Neogen Corporation)
• FY2025 10-K: 000711377 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-01 2024-05-31 0000711377 neog:FoodSafetyMember neog:RodenticidesInsecticidesAndDisinfectantsMember 2023-06-01 2024-05-31 0000711377 neog:AnimalSafetyMember neog:RodenticidesInsecticidesAndDisinfectantsMember 2022-06-01 2023-05-31 0000711377…
• FY2025 10-K: …2023-06-01 2024-05-31 0000711377 neog:AnimalSafetyMember neog:RodenticidesInsecticidesAndDisinfectantsMember 2024-06-01 2025-05-31 0000711377 neog:ExercisePricesRangeTwoMember 2024-06-01 2025-05-31 0000711377 neog:CreditAgreementMember neog:TermLoanFacilityMember 2022-06-30 0000711377…
• PAHC (Phibro Animal Health Corporation)
• FY2025 10-K: …0.0001 0.0001 http://fasb.org/srt/2025#ChiefExecutiveOfficerMember http://fasb.org/srt/2025#ChiefExecutiveOfficerMember http://fasb.org/srt/2025#ChiefExecutiveOfficerMember http://www.pahc.com/20250630#AnimalHealthMember http://www.pahc.com/20250630#AnimalHealthMember http://www.pahc.com/20250630#AnimalHealthMember…
• FY2025 10-K: …change and cannot always be verified due to limits on the availability and reliability of independent sources, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey of market shares. In addition, purchasing patterns and consumer preferences can…

Water (reported)

• ZTS (Zoetis Inc.)
• FY2025 10-K: …frequency of wildfires and other natural disasters, rising sea levels, and a rising heat index, any of which could cause negative impacts to our and our customers' and suppliers' businesses. The physical changes caused by climate change may also prompt changes in regulations or consumer preferences which in turn…
• FY2025 10-K: …our operating results and financial condition, especially if such interruptions to regular operations are frequent or prolonged. Weather conditions, including excessive cold or heat, natural disasters, floods, droughts and other events, could negatively impact our livestock customers by impairing the health or growth…
• ELAN (Elanco Animal Health Incorporated)
• FY2025 10-K: …70% and 60% of the total revenue for our higher-margin parasiticide products Seresto and Advantage Family , respectively, was generated in the first half of the year, reflective of the flea and tick season in the Northern Hemisphere. As such, fluctuations in our revenue due to seasonality and/or weather or…
• FY2025 10-K: …and discounts liability for the years ended December 31: 2025 2024 Beginning balance $ 332 $ 367 Reduction of revenue 969 799 Payments ( 901 ) ( 824 ) Foreign currency translation adjustments 16 ( 10 ) Ending balance $ 416 $ 332 Adjustments to revenue recognized as a result of changes in estimates during the years…
• NEOG (Neogen Corporation)
• FY2025 10-K: …successfully accepted in the marketplace; • transition to in-house manufacturing of Petrifilm; • expanding our markets by fostering increased use of our products by customers; • maintaining or increasing gross and net operating margins in changing cost environments; • strengthening operations and sales and marketing…
• FY2025 10-K: …such as hurricanes, tropical storms, blizzards, tornadoes, earthquakes, wildfires or flooding. Such extreme weather conditions could pose physical risks to our facilities and disrupt our operations and impair our critical systems, and may impact raw material sourcing, manufacturing operations, the distribution of our…
• PAHC (Phibro Animal Health Corporation)
• FY2025 10-K: …United States and member states of the E. U."; "Business -Compliance with Government Regulation - United States - Carbadox"; and "Business - Compliance with Government Regulation - Global Policy and Guidance." A material portion of our sales are generated by antibacterials and other related products. Our medicated…
• FY2025 10-K: …event of adverse weather conditions or a shortage of fresh water, livestock producers may purchase less of our products. Adverse weather conditions, including excessive cold or heat, natural disasters, floods, droughts and other events, could negatively impact our livestock customers by impairing the health or growth…
• QGEN (QIAGEN N.V.)
• FY2025 20-F: Page 9 Strategy, Business Model and Value Chain Downstream Upstream Our operations Procurement Sales to >500,000 customers in > 160 countries Sales entities in EMEA, APAC and Americas Raw materials R&D services and in-licensing Finished goods Logistical and warehousing services Semi-finished goods IT and other…
• FY2025 20-F: …of new breakthroughs that can lead to new medicines and diagnostics for use in clinical healthcare. This market also includes the use of molecular testing technologies for applied applications, in particular for forensics as well as food and veterinary testing. These customers are all often served by public funding…
• TECH (BIO-TECHNE Corp)
• FY2025 10-K: …reporting but will have no impact on reported income statement expenses. Other than the items noted above, there have been no new accounting pronouncements not yet effective that we believe have a significant impact, or potential significant impact, on our Consolidated Financial Statements. Note 2 . Revenue…
• FY2025 10-K: …Location ​ June 30, ​ Inputs Considered as ​ ​ ​ 2025 ​ Level 1 ​ Level 2 ​ Level 3 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ ​ Derivatives designated as hedging instruments - cash flow hedges Other current assets ​ $ 2,843 ​ $ - ​ $ 2,843 ​ $ - Total assets ​ ​ $ 2,843 ​ $ - ​ $ 2,843 ​ $ - ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​…
• LNTH (LANTHEUS HOLDINGS, INC.)
• FY2025 10-K: …associated with the Company's SPECT business, which was completed on January 1, 2026 (see Note 8 "Assets and Liabilities Held for Sale" to our consolidated financial statements included in Part II, Item 8 "Financial Statements and Supplementary Data" of this Form 10-K. We currently provide this financial assurance in…
• FY2025 10-K: …available Gallium-68-based PSMA PET imaging agents, two from Telix Pharmaceuticals Limited and one from Novartis AG and an F-18 PSMA PET imaging agent from Blue Earth Diagnostics Ltd. ("Blue Earth"), as well as other non-PSMA PET imaging agents. The potential for future generic entrants to the market due to the…

LPD (Livestock, Poultry and Dairy) (reported)

• ZTS (Zoetis Inc.)
• FY2025 10-K: …access to customer decision makers as compared to those in human health. In certain markets, including the U.S., pet owners are taking a more active role in product purchasing decisions, and as a result we are increasingly investing in direct-to-consumer marketing efforts. As of December 31, 2025, our sales…
• FY2025 10-K: …and can rely on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Estimates and Assumptions . 4. Revenue A. Revenue from Product Sales We offer a diversified portfolio of products which allows us to capitalize on local and regional customer needs. Generally, our…
• ELAN (Elanco Animal Health Incorporated)
• FY2025 10-K: …on animal-derived protein, reduced herd or flock sizes or reduced demand for animal-derived protein, any of which may have a material adverse effect on our business, financial condition and results of operations. Our R&D relies on evaluations of animals and may become subject to bans, additional restrictive…
• FY2025 10-K: …products to third-party distributors and directly to a diverse set of farm animal producers, including beef, dairy, pork and poultry operations. Our omnichannel presence allows us to sell into both the veterinary clinic and retail markets, including e-commerce. 9 Table of Contents Certain top selling pet health…
• PAHC (Phibro Animal Health Corporation)
• FY2025 10-K: ​ maduramycin + nicarbazin ​ Anticoccidial for poultry Deccox ® / Avi-Deccox ® * ​ decoquinate ​ Anticoccidial for poultry and cattle Robenz ® / Cycostat ® * ​ robenidine ​ Anticoccidial for poultry Zoamix ® * ​ zoalene ​ Anticoccidial for poultry BMD ® * ​ bacitracin methylenedisalicylate ​ Antibacterial for poultry…
• FY2025 10-K: …Federal Food, Drug, and Cosmetic Act. An approved Abbreviated New Animal Drug Application ("ANADA") is a generic equivalent of an NADA previously approved by the FDA. Both are regulated by the FDA. However, because human food safety and environmental safety are issues for food-producing animals, the animal drug…
• NEOG (Neogen Corporation)
• FY2025 10-K: …is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development,…
• FY2025 10-K: …grain , including grain elevators, feed mills, pet food manufacturers and grain inspection companies; • Meat and poultry , including meat and poultry processors, producers of ready-to-eat meat and poultry products, and the USDA's Food Safety and Inspection Service (FSIS); • Ready-to-eat , including flour millers,…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.